Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health, Inc. director and Chief Policy Officer Deborah M Autor reported selling 7,054 shares of Class A common stock on December 17, 2025 at $36.71 per share. The transaction was filed on Form 4 as a sale of non-derivative securities.
After this sale, she beneficially owned 6,175 shares of Class A common stock, held directly. The filing notes that the sale was effected under a Rule 10b5-1 trading plan adopted on August 11, 2025, indicating the trades followed a pre-established plan.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison Carroll reported selling 10,021 shares of Class A common stock on 12/17/2025 at $36.71 per share.
After this transaction, Carroll beneficially owns 169,940 shares of Hims & Hers Class A common stock, held directly. The sale was carried out pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025.
Hims & Hers Health, Inc. officer Irene Becklund reported selling 8,411 shares of Class A common stock on 12/17/2025 at $36.71 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2024. After this transaction, she directly holds 2,126 shares of Hims & Hers Health stock.
A shareholder has filed a notice of proposed sale covering 10,021 Class A shares, to be sold through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of 367,870.91. The filing lists an approximate sale date of 12/17/2025.
The shares were acquired on 12/15/2025 through restricted stock vesting from the issuer as compensation. The same seller, Patrick H. Carroll, is also disclosed as having sold 10,021 Class A shares on 09/17/2025 for gross proceeds of 506,060.50 during the prior three months.
This notice reports that shareholder Michael Y. Chi plans to sell 13,750 Class A shares of the issuer on or about 12/17/2025 through Fidelity Brokerage Services on the NYSE. The shares have an aggregate market value of $504,762.50, while total Class A shares outstanding are 219,270,891.
The securities to be sold were acquired from the issuer on 12/15/2025 through restricted stock vesting as compensation, with the same date listed for acquisition and payment. The filing also lists several prior Class A share sales by Michael Y. Chi over the past three months, including 13,749 shares sold on 09/17/2025 for gross proceeds of $694,324.50.
HIMS stockholder Irene Becklund has filed a notice to sell 8,411 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $308,767.81. The notice also lists 219,270,891 Class A shares outstanding.
The shares to be sold were acquired on 12/15/2025 via restricted stock vesting from the issuer as compensation, with payment also dated that day. Over the prior three months, Becklund sold 8,410 Class A shares on 09/17/2025 for gross proceeds of $424,705.00.
A holder of HIMS Class A stock has filed a Rule 144 notice to sell 7054 shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 258952.34 and an approximate sale date of 12/17/2025. These Class A shares were acquired from the issuer on 12/15/2025 via restricted stock vesting as compensation, in the same amount of 7054 shares. The notice lists 219270891 Class A shares outstanding, providing context for the planned sale.
Hims & Hers Health, Inc. reported an insider equity transaction by Chief Legal Officer Soleil Boughton. On December 15, 2025, restricted stock units (RSUs) converted into 41,421 shares of Class A common stock. To cover tax withholding obligations from this vesting, the company withheld 22,817 Class A shares at $36.25 per share, after which Boughton directly owned 171,829 Class A shares.
The reported RSUs each represent a contingent right to receive one share of Class A common stock. Several RSU grants are subject to service-based vesting over four years, in substantially equal quarterly installments on Company Quarterly Vesting Dates, with first vesting dates beginning on June 15, 2022, June 15, 2023, June 15, 2024, and June 15, 2025.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison Carroll reported equity compensation activity dated December 15, 2025. Restricted stock units (RSUs) converted into 16,521 shares of Class A common stock (transaction code M), increasing his direct holdings to 186,461 shares before tax withholding.
The issuer then withheld 6,500 shares at $36.25 per share (transaction code F) to satisfy tax withholding obligations tied to the RSU vesting, leaving Carroll with 179,961 directly held shares. The RSUs vest over four-year service periods: one grant vests 25% on December 15, 2023 with the remainder in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, and additional grants vest quarterly on these same Company Quarterly Vesting Dates starting June 15, 2024 and June 15, 2025.
Hims & Hers Health, Inc. reported insider equity activity by its chief executive officer, who is also a director and 10% owner, on December 15, 2025. The filing shows the acquisition of 164,369 shares of Class A Common Stock through the settlement of restricted stock units.
On the same date, 90,660 shares of Class A Common Stock were disposed of at $36.25 per share, as the issuer withheld these shares to cover tax withholding obligations related to the RSU vesting. Following these transactions, the reporting person held 878,732 Class A shares directly, in addition to substantial indirect holdings through multiple family trusts.
The RSU awards each convert into one share of Class A Common Stock and are subject to four-year, service-based vesting in substantially equal quarterly installments on Company Quarterly Vesting Dates. Depending on the grant, these quarterly vesting schedules began on June 15, 2022, June 15, 2023, June 15, 2024 and June 15, 2025.